138 related articles for article (PubMed ID: 20958260)
1. Streamlined in vivo selection and screening of human prostate carcinoma avid phage particles for development of peptide based in vivo tumor imaging agents.
Newton-Northup JR; Figueroa SD; Deutscher SL
Comb Chem High Throughput Screen; 2011 Jan; 14(1):9-21. PubMed ID: 20958260
[TBL] [Abstract][Full Text] [Related]
2. Bifunctional phage-based pretargeted imaging of human prostate carcinoma.
Newton-Northup JR; Figueroa SD; Quinn TP; Deutscher SL
Nucl Med Biol; 2009 Oct; 36(7):789-800. PubMed ID: 19720291
[TBL] [Abstract][Full Text] [Related]
3. In vivo selection of phage for the optical imaging of PC-3 human prostate carcinoma in mice.
Newton JR; Kelly KA; Mahmood U; Weissleder R; Deutscher SL
Neoplasia; 2006 Sep; 8(9):772-80. PubMed ID: 16984734
[TBL] [Abstract][Full Text] [Related]
4. Characterization of In Vivo Selected Bacteriophage for the Development of Novel Tumor-Targeting Agents with Specific Pharmacokinetics and Imaging Applications.
Newton-Northup J; Deutscher SL
Methods Mol Biol; 2017; 1572():445-465. PubMed ID: 28299705
[TBL] [Abstract][Full Text] [Related]
5. Cytotoxic Tumor-Targeting Peptides From In Vivo Phage Display.
Northup JR; Deutscher SL
Comb Chem High Throughput Screen; 2016; 19(5):370-7. PubMed ID: 27055748
[TBL] [Abstract][Full Text] [Related]
6. In vivo bacteriophage peptide display to tailor pharmacokinetics of biological nanoparticles.
Newton-Northup JR; Dickerson MT; Kumar SR; Smith GP; Quinn TP; Deutscher SL
Mol Imaging Biol; 2014 Dec; 16(6):854-64. PubMed ID: 25001195
[TBL] [Abstract][Full Text] [Related]
7. In vitro high throughput phage display selection of ovarian cancer avid phage clones for near-infrared optical imaging.
Soendergaard M; Newton-Northup JR; Deutscher SL
Comb Chem High Throughput Screen; 2014; 17(10):859-67. PubMed ID: 25360673
[TBL] [Abstract][Full Text] [Related]
8. Affinity maturation of an ERBB2-targeted SPECT imaging peptide by in vivo phage display.
Larimer BM; Thomas WD; Smith GP; Deutscher SL
Mol Imaging Biol; 2014 Aug; 16(4):449-58. PubMed ID: 24550054
[TBL] [Abstract][Full Text] [Related]
9. Discovery of peptide drug carrier candidates for targeted multi-drug delivery into prostate cancer cells.
Bashari O; Redko B; Cohen A; Luboshits G; Gellerman G; Firer MA
Cancer Lett; 2017 Nov; 408():164-173. PubMed ID: 28888997
[TBL] [Abstract][Full Text] [Related]
10. Tumor targeting and SPECT imaging properties of an (111)In-labeled galectin-3 binding peptide in prostate carcinoma.
Deutscher SL; Figueroa SD; Kumar SR
Nucl Med Biol; 2009 Feb; 36(2):137-46. PubMed ID: 19217525
[TBL] [Abstract][Full Text] [Related]
11. 111In-labeled galectin-3-targeting peptide as a SPECT agent for imaging breast tumors.
Kumar SR; Deutscher SL
J Nucl Med; 2008 May; 49(5):796-803. PubMed ID: 18413389
[TBL] [Abstract][Full Text] [Related]
12. Screening of a specific peptide binding to esophageal squamous carcinoma cells from phage displayed peptide library.
Ma C; Li C; Jiang D; Gao X; Han J; Xu N; Wu Q; Nie G; Chen W; Lin F; Hou Y
Mol Cell Probes; 2015 Jun; 29(3):182-9. PubMed ID: 25886968
[TBL] [Abstract][Full Text] [Related]
13. Peptide-conjugated nanoparticles for targeted imaging and therapy of prostate cancer.
Yeh CY; Hsiao JK; Wang YP; Lan CH; Wu HC
Biomaterials; 2016 Aug; 99():1-15. PubMed ID: 27209258
[TBL] [Abstract][Full Text] [Related]
14. Melanoma imaging with pretargeted bivalent bacteriophage.
Newton JR; Miao Y; Deutscher SL; Quinn TP
J Nucl Med; 2007 Mar; 48(3):429-36. PubMed ID: 17332621
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of an 111In-radiolabeled peptide as a targeting and imaging agent for ErbB-2 receptor expressing breast carcinomas.
Kumar SR; Quinn TP; Deutscher SL
Clin Cancer Res; 2007 Oct; 13(20):6070-9. PubMed ID: 17947470
[TBL] [Abstract][Full Text] [Related]
16. Labeling and distribution of linear peptides identified using in vivo phage display selection for tumors.
Kennel SJ; Mirzadeh S; Hurst GB; Foote LJ; Lankford TK; Glowienka KA; Chappell LL; Kelso JR; Davern SM; Safavy A; Brechbiel MW
Nucl Med Biol; 2000 Nov; 27(8):815-25. PubMed ID: 11150716
[TBL] [Abstract][Full Text] [Related]
17. Fully synthetic phage-like system for screening mixtures of small molecules in live cells.
Byk G; Partouche S; Weiss A; Margel S; Khandadash R
J Comb Chem; 2010 May; 12(3):332-45. PubMed ID: 20345088
[TBL] [Abstract][Full Text] [Related]
18. Landscape phage fusion protein-mediated targeting of nanomedicines enhances their prostate tumor cell association and cytotoxic efficiency.
Jayanna PK; Bedi D; Gillespie JW; DeInnocentes P; Wang T; Torchilin VP; Bird RC; Petrenko VA
Nanomedicine; 2010 Aug; 6(4):538-46. PubMed ID: 20138246
[TBL] [Abstract][Full Text] [Related]
19. In vivo phage display selection of an ovarian cancer targeting peptide for SPECT/CT imaging.
Soendergaard M; Newton-Northup JR; Deutscher SL
Am J Nucl Med Mol Imaging; 2014; 4(6):561-70. PubMed ID: 25250205
[TBL] [Abstract][Full Text] [Related]
20. Metastatic prostate cancer cell-specific phage-like particles as a targeted gene-delivery system.
Fagbohun OA; Kazmierczak RA; Petrenko VA; Eisenstark A
J Nanobiotechnology; 2013 Sep; 11():31. PubMed ID: 24059645
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
